Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer

3739 Cases From the National Cancer Data Base

Alina M. Mateo, Todd A. Pezzi, Mark Sundermeyer, Cynthia A. Kelley, Vicki Klimberg, Christopher M. Pezzi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of adjuvant chemotherapy has not been extensively studied. Methods: Female patients with invasive MBC reported to the National Cancer Data Base from 2004 to 2012 were analyzed. Overall survival (OS) and treatment were studied using the Kaplan–Meier method and the Cox proportional hazard model. Patients who had node-negative (N0), non-metastatic (M0) tumors 10 to 50 mm in size (T1cN0M0 and T2N0M0) treated with and without chemotherapy were analyzed using propensity score matching. Results: Of 3739 patients with MBC, 2642 (71%) had T1b-T2N0M0 disease treated with and without chemotherapy. Multivariable analysis showed that for all MBC patients, the significant predictors of OS were age older than 65 years, one or more comorbidities, tumor larger than 2 cm, positive nodes, distant metastasis, and treatment with chemotherapy or radiation therapy. Patients with T1cN0M0 and T2N0M0 had improved OS if they received chemotherapy (p < 0.0005). Patients with T1bN0M0 who received chemotherapy did not show better OS than those who did not. Patients with T1c-T2N0M0 were then matched by propensity score based on age, presence of comorbidities, tumor size, and treatment methods used. After matching, the group receiving chemotherapy showed an improved OS (hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.26–0.62; p < 0.0005) compared to the group that did not receive chemotherapy. Conclusions: For patients with T1c-T2N0M0 MBC, chemotherapy significantly improves OS.

Original languageEnglish (US)
Pages (from-to)1050-1056
Number of pages7
JournalAnnals of Surgical Oncology
Volume24
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Databases
Breast Neoplasms
Drug Therapy
Survival
Neoplasms
Propensity Score
Comorbidity
Adjuvant Chemotherapy
Proportional Hazards Models
Radiotherapy
Therapeutics
Confidence Intervals
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer : 3739 Cases From the National Cancer Data Base. / Mateo, Alina M.; Pezzi, Todd A.; Sundermeyer, Mark; Kelley, Cynthia A.; Klimberg, Vicki; Pezzi, Christopher M.

In: Annals of Surgical Oncology, Vol. 24, No. 4, 01.04.2017, p. 1050-1056.

Research output: Contribution to journalArticle

Mateo, Alina M. ; Pezzi, Todd A. ; Sundermeyer, Mark ; Kelley, Cynthia A. ; Klimberg, Vicki ; Pezzi, Christopher M. / Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer : 3739 Cases From the National Cancer Data Base. In: Annals of Surgical Oncology. 2017 ; Vol. 24, No. 4. pp. 1050-1056.
@article{50068dbe64ea4ef5b0538ffbe91df14a,
title = "Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base",
abstract = "Background: Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of adjuvant chemotherapy has not been extensively studied. Methods: Female patients with invasive MBC reported to the National Cancer Data Base from 2004 to 2012 were analyzed. Overall survival (OS) and treatment were studied using the Kaplan–Meier method and the Cox proportional hazard model. Patients who had node-negative (N0), non-metastatic (M0) tumors 10 to 50 mm in size (T1cN0M0 and T2N0M0) treated with and without chemotherapy were analyzed using propensity score matching. Results: Of 3739 patients with MBC, 2642 (71{\%}) had T1b-T2N0M0 disease treated with and without chemotherapy. Multivariable analysis showed that for all MBC patients, the significant predictors of OS were age older than 65 years, one or more comorbidities, tumor larger than 2 cm, positive nodes, distant metastasis, and treatment with chemotherapy or radiation therapy. Patients with T1cN0M0 and T2N0M0 had improved OS if they received chemotherapy (p < 0.0005). Patients with T1bN0M0 who received chemotherapy did not show better OS than those who did not. Patients with T1c-T2N0M0 were then matched by propensity score based on age, presence of comorbidities, tumor size, and treatment methods used. After matching, the group receiving chemotherapy showed an improved OS (hazard ratio [HR], 0.40; 95{\%} confidence interval [CI], 0.26–0.62; p < 0.0005) compared to the group that did not receive chemotherapy. Conclusions: For patients with T1c-T2N0M0 MBC, chemotherapy significantly improves OS.",
author = "Mateo, {Alina M.} and Pezzi, {Todd A.} and Mark Sundermeyer and Kelley, {Cynthia A.} and Vicki Klimberg and Pezzi, {Christopher M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1245/s10434-016-5649-6",
language = "English (US)",
volume = "24",
pages = "1050--1056",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer

T2 - 3739 Cases From the National Cancer Data Base

AU - Mateo, Alina M.

AU - Pezzi, Todd A.

AU - Sundermeyer, Mark

AU - Kelley, Cynthia A.

AU - Klimberg, Vicki

AU - Pezzi, Christopher M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of adjuvant chemotherapy has not been extensively studied. Methods: Female patients with invasive MBC reported to the National Cancer Data Base from 2004 to 2012 were analyzed. Overall survival (OS) and treatment were studied using the Kaplan–Meier method and the Cox proportional hazard model. Patients who had node-negative (N0), non-metastatic (M0) tumors 10 to 50 mm in size (T1cN0M0 and T2N0M0) treated with and without chemotherapy were analyzed using propensity score matching. Results: Of 3739 patients with MBC, 2642 (71%) had T1b-T2N0M0 disease treated with and without chemotherapy. Multivariable analysis showed that for all MBC patients, the significant predictors of OS were age older than 65 years, one or more comorbidities, tumor larger than 2 cm, positive nodes, distant metastasis, and treatment with chemotherapy or radiation therapy. Patients with T1cN0M0 and T2N0M0 had improved OS if they received chemotherapy (p < 0.0005). Patients with T1bN0M0 who received chemotherapy did not show better OS than those who did not. Patients with T1c-T2N0M0 were then matched by propensity score based on age, presence of comorbidities, tumor size, and treatment methods used. After matching, the group receiving chemotherapy showed an improved OS (hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.26–0.62; p < 0.0005) compared to the group that did not receive chemotherapy. Conclusions: For patients with T1c-T2N0M0 MBC, chemotherapy significantly improves OS.

AB - Background: Medullary breast cancer (MBC) is a rare tumor associated with a better prognosis compared with other breast cancers. The role of adjuvant chemotherapy has not been extensively studied. Methods: Female patients with invasive MBC reported to the National Cancer Data Base from 2004 to 2012 were analyzed. Overall survival (OS) and treatment were studied using the Kaplan–Meier method and the Cox proportional hazard model. Patients who had node-negative (N0), non-metastatic (M0) tumors 10 to 50 mm in size (T1cN0M0 and T2N0M0) treated with and without chemotherapy were analyzed using propensity score matching. Results: Of 3739 patients with MBC, 2642 (71%) had T1b-T2N0M0 disease treated with and without chemotherapy. Multivariable analysis showed that for all MBC patients, the significant predictors of OS were age older than 65 years, one or more comorbidities, tumor larger than 2 cm, positive nodes, distant metastasis, and treatment with chemotherapy or radiation therapy. Patients with T1cN0M0 and T2N0M0 had improved OS if they received chemotherapy (p < 0.0005). Patients with T1bN0M0 who received chemotherapy did not show better OS than those who did not. Patients with T1c-T2N0M0 were then matched by propensity score based on age, presence of comorbidities, tumor size, and treatment methods used. After matching, the group receiving chemotherapy showed an improved OS (hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.26–0.62; p < 0.0005) compared to the group that did not receive chemotherapy. Conclusions: For patients with T1c-T2N0M0 MBC, chemotherapy significantly improves OS.

UR - http://www.scopus.com/inward/record.url?scp=84994324048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994324048&partnerID=8YFLogxK

U2 - 10.1245/s10434-016-5649-6

DO - 10.1245/s10434-016-5649-6

M3 - Article

VL - 24

SP - 1050

EP - 1056

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -